Aptorum Group Net Profit Margin 2018-2023 | APM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Aptorum Group net profit margin from 2018 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Aptorum Group net profit margin from 2018 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.8B
Takeda Pharmaceutical (TAK)	$42.6B
Sandoz Group AG (SDZNY)	$19.5B
Merck (MKKGY)	$19.1B
Astellas Pharma (ALPMY)	$18.3B
United Therapeutics (UTHR)	$16.6B
Summit Therapeutics (SMMT)	$14B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$12B
Catalent (CTLT)	$11.1B
Madrigal Pharmaceuticals (MDGL)	$7.6B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$6B
Ionis Pharmaceuticals (IONS)	$5.4B
Crinetics Pharmaceuticals (CRNX)	$5.2B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Soleno Therapeutics (SLNO)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
NewAmsterdam Pharma (NAMS)	$1.9B
Xencor (XNCR)	$1.8B
Recursion Pharmaceuticals (RXRX)	$1.6B
Evotec AG (EVO)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Harrow (HROW)	$1.5B
Indivior (INDV)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.5B
Ocular Therapeutix (OCUL)	$1.4B